Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 99

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 99
---
 difficult for us to attain profitability.” As a result
of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research
and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

General
and Administrative Expenses

General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.

We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur additional expenses as a result of operating as
a public company, including expenses related to compliance with the rules and regulations of the SEC, additional director and officer
insurance expenses, investor relations activities, and other administrative and professional services.

Other
Income, Net

Other
income, net includes interest earned on deposits and investments and other items of income, expense, gain and loss that are incidental
to the core operations of the Company.

Results
of Operations

Year
Ended December 31, 2024 compared to Year Ended December 31, 2023

The
following tables set forth our results of operations for the years ended December 31, 2024 and 2023 and the relative dollar and percentage
change between the two years.

    Year ended December 31,  
    Change (2024 to 2023) 

    2024  
    2023  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $7,251,097  
    $7,621,707  
    $(370,610) 
     (4.9)%
  
    General and administrative 
     8,114,654  
     8,756,767  
     (642,113) 
     (7.3)%
  
    Total operating expenses 
     15,365,751  
     16,378,474  
     (1,012,723) 
     (6